Prevention of hyponatraemia and cerebral oedema by the vasopressin antagonist d/CH(2/5)Tyr/Et/VAVP in rats treated with pitressin tannate

F. A. Laszlo, S. Csati, L. Balaspiri

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

A rat model of the Schwartz-Bartter syndrome was created by the administration of a high dose of a long-acting vasopressin preparation (pitressin tannate) together with a forced water intake. The treatment led to water retention, hypernatriuria, marked hyponatraemia (in 4-5 days) and severe cerebral oedema. These changes could be prevented by the simultaneous administration of [1-(β-mercapto-β,β-cyclopentamethylene-propionic acid),2-0-ethyltyrosine,4-valine]arginine vasopressin. The observations indicate that this vasopressin antagonist analogue might be of use in the future as an effective drug against the Schwartz-Bartter syndrome.

Original languageEnglish
Pages (from-to)56-60
Number of pages5
JournalActa endocrinologica
Volume106
Issue number1
Publication statusPublished - Jan 1 1984

ASJC Scopus subject areas

  • Endocrinology

Fingerprint Dive into the research topics of 'Prevention of hyponatraemia and cerebral oedema by the vasopressin antagonist d/CH(2/5)Tyr/Et/VAVP in rats treated with pitressin tannate'. Together they form a unique fingerprint.

  • Cite this